Discovery of CC Chemokine Receptor-3 (CCR3) Antagonists with Picomolar Potency
摘要:
Starting with our previously described(20) class of CC chemokine receptor-3 (CCR3) antagonist, we improved the potency by replacing the phenyl linker of 1 with a cyclohexyl linker and by replacing the 4-benzylpiperidine with a 3-benzylpiperidine. The resulting compound, 32, is a potent and selective antagonist of CCR3. SAR studies showed that the 3-acetylphenyl urea of 32 could be replaced with heterocyclic ureas or heterocyclic-substituted phenyl ureas and still maintain the potency (inhibition of eotaxin-induced chemotaxis) of this class of compounds in the low-picomolar range (IC50 = 10-60 pM), representing some of the most potent CCR3 antagonists reported to date. The potency of 32 for mouse CCR3 (chemotaxis IC50 = 41 nM) and its oral bioavailability in mice (20% F) were adequate to assess the efficacy in animal models of allergic airway inflammation. Oral administration of 32 reduced eosinophil recruitment into the lungs in a dose-dependent manner in these animal models. On the basis of its overall potency, selectivity, efficacy, and safety profile, the benzenesulfonate salt of 32, designated DPC168, entered phase 1 clinical trials.
Axl 通常在许多癌症中过度表达,并与肿瘤生长、转移、耐药性和较差的总体生存率相关,因此已成为癌症治疗的一个有前景的靶点。然而,用于 Axl 抑制的新化学形式的可用性是有限的。在此,我们介绍了新型 Axl 抑制剂的开发和表征,包括一系列二苯基嘧啶二胺衍生物的设计、合成和构效关系 (SAR)。这些化合物中的大多数都表现出显着的抗 Axl 激酶活性。特别是,有前途的化合物m16显示出最高的酶抑制效力(IC 50 = 5 nM)并阻断多种肿瘤细胞的增殖效力( 42 个癌细胞系中 4 个的CC 50 <100 nM)。此外,化合物m16还具有较好的药代动力学特征和肝微粒体稳定性。所有这些有利的结果使m16成为进一步开发的良好领先治疗候选药物。